Berlin Noa, Shekhar Aditya C, Berg Katherine M
Center for Resuscitation Science, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA.
J Thorac Dis. 2024 Jan 30;16(1):661-670. doi: 10.21037/jtd-23-105. Epub 2024 Jan 29.
Shenfu injection (SFI) is a traditional herbal medicine derived from components of ginseng and aconite and is commonly used in China to treat a variety of conditions. Shenfu has been suggested to have beneficial effects in various critical illnesses, including heart failure, cardiac arrest, and septic shock. In recent years, there have been a number of studies reporting that SFI improves patient outcomes when used concurrently with other treatments, but its use has not been adopted outside of China. This narrative review explored the results of clinical trials that have tested SFI's efficacy in various critical illnesses.
PubMed was searched for clinical trials, systematic reviews and meta-analyses published between 1990 and July 2022 relating to clinical trials using SFI in various critical illnesses. Systematic reviews and meta-analyses were included to enable inclusion of data from trials originally not published in English. The selected articles were then summarized in the following disease categories: heart failure, cardiac arrest, sepsis, and severe pulmonary disease.
Clinical trials testing SFI in heart failure, cardiac arrest, sepsis, and pulmonary disease were reviewed. The design, methodology, and key findings of each trial or meta-analysis are summarized and discussed. Key limitations were also highlighted and discussed. Overall, several clinical trials suggest SFI may hold therapeutic potential for the treatment of critical illness, however, additional research is likely still needed.
Based on the current body of literature, further research-especially multi-center randomized, double-blind trials with detailed reporting of all methods and results according to international guidelines-is needed to evaluate whether SFI is a useful addition to existing treatments for these conditions.
参附注射液（SFI）是一种源自人参和附子成分的传统草药，在中国常用于治疗多种病症。参附被认为对包括心力衰竭、心脏骤停和感染性休克在内的各种危重病有益。近年来，有多项研究报告称，参附注射液与其他治疗方法同时使用时可改善患者预后，但其应用尚未在中国以外地区采用。本叙述性综述探讨了测试参附注射液在各种危重病中疗效的临床试验结果。
在PubMed上检索1990年至2022年7月间发表的有关在各种危重病中使用参附注射液的临床试验、系统评价和荟萃分析。纳入系统评价和荟萃分析，以便纳入最初未以英文发表的试验数据。然后将所选文章按以下疾病类别进行总结：心力衰竭、心脏骤停、脓毒症和重症肺部疾病。
对在心力衰竭、心脏骤停、脓毒症和肺部疾病中测试参附注射液的临床试验进行了综述。总结并讨论了每项试验或荟萃分析的设计、方法和主要发现。还强调并讨论了关键局限性。总体而言，多项临床试验表明参附注射液可能对危重病的治疗具有治疗潜力，然而，可能仍需要更多研究。
基于目前的文献资料，需要进一步研究——尤其是多中心随机双盲试验，并根据国际指南详细报告所有方法和结果——以评估参附注射液是否是这些病症现有治疗方法的有益补充。
